GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of ...

The US Food and Drug Administration (FDA) has approved fluticasone furoate inhalation powder (Arnuity Ellipta, GlaxoSmithKline) as maintenance treatment for asthma in patients aged 12 years and older, ...

The FDA has approved fluticasone furoate inhalation powder as a once-daily corticosteroid for maintenance treatment of asthma in patients aged 12 and older, according to a press release. Fluticasone ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. ARNUITY ELLIPTA contains the active ingredient fluticasone furoate.

Please provide your email address to receive an email when new articles are posted on . GlaxoSmithKline announced that the FDA has approved Arnuity Ellipta, a once-daily inhaled corticosteroid, for ...

GlaxoSmithKline’s inhaled corticosteroid Arnuity Ellipta has been approved in the US for paediatric use. GlaxoSmithKline’s inhaled corticosteroid Arnuity Ellipta has been approved in the US for ...

GlaxoSmithKline ( GSK) received positive news when the FDA approved its asthma treatment, Arnuity Ellipta. Arnuity Ellipta has been approved in doses of 100 mcg and 200 mcg as a once-daily inhaled ...

Fluticasone furoate 50mcg, 100mcg, 200mcg; per inhalation; dry pwd for oral inhalation. Do not exceed recommended dose. Prescribe a short-acting, inhaled β 2-agonist for acute symptoms; monitor for ...